NAT DIAGNOSTICS
NAT Diagnostics is focused on providing a better diagnostic experience for the patient. They develop a molecular diagnostic platform that will provide true Point-of-Care testing for infectious disease in the physicians’ offices, clinics, pharmacies, and other sites where patients are seen by medical personnel, with highly accurate results available to the doctor and the patient in 10 minutes. The company was founded in 2014 and is headquartered in San Diego, California.
NAT DIAGNOSTICS
Industry:
Health Care Health Diagnostics Personal Health
Founded:
2014-01-01
Address:
San Diego, California, United States
Country:
United States
Website Url:
http://www.natdx.com
Total Employee:
11+
Status:
Active
Total Funding:
4.41 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Apache IPv6 Microsoft Azure DNS PHP PHP 7 Mobile Optimized Drupal 1and1
Similar Organizations
Fastic
Your go-to partner for everyday well-being.
Juno Diagnostics
Juno Diagnostics is a healthcare technology company developing the next generation cell-free DNA-based noninvasive prenatal test solutions.
Lin Health
Lin is an online pain care plan that delivers integrative, personalized, science-based programs by experts who really care.
Current Employees Featured
Founder
Official Site Inspections
http://www.natdx.com Semrush global rank: 5.25 M Semrush visits lastest month: 1.56 K
Unable to get host informations!!!
More informations about "NAT Diagnostics"
Home - NavDx
Routine testing with NavDx, to track and monitor changes in blood TTMV offers a more complete picture of HPV-driven cancer status than simply relying on physical exams and imaging. …See details»
WHAT IS NavDx®? - Naveris
NavDx is the first and only clinically validated circulating tumor-tissue–modified HPV (TTMV®) DNA blood test that aids in the detection of HPV-driven cancer. NavDx uses proprietary technology to quantify fragments of circulating TTMV …See details»
Physician - NavDx
Use NavDx and optimize HPV-driven head and neck cancer care—track their TTMV Scores pretreatment, during treatment and for recurrence monitoring. Explore How. ... Switzerland: World Health Organization, 2007. 8. Mijares K, …See details»
Naveris | Transformative Technologies for Early Cancer …
Naveris’ lead product, NavDx®, is a liquid biopsy that uses proprietary technology to enable ultrasensitive surveillance of HPV-related cancer. NavDx Liquid Biopsy. Our Core Technology. Our mission at Naveris is to deliver disruptive …See details»
Patient - NavDx
Routine testing with NavDx to track changes in your TTMV ® Score offers your physician a more complete picture of your cancer status than imaging scans alone. With a simple blood draw, NavDx can detect whether the tumor has …See details»
Naveris - Crunchbase Company Profile & Funding
Organization. Naveris . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. ... NavDx: A liquid biopsy test that analyzes tumor-tissue-modified DNA in the blood to detect HPV-related …See details»
Information for Physicians | Naveris | Early …
NavDx® is the first and only clinically validated circulating tumor-tissue-modified HPV (TTMV) DNA blood test that can aid in the detection of HPV-driven cancer.¹Ë’³. NavDx uncovers the …See details»
Naveris Announces Expansion of the NavDx - Business Wire
Jan 10, 2025 NavDx, Naveris’ proprietary flagship blood test, is the first and only clinically validated circulating tumor TTMV ®-HPV DNA blood test that provides a non-invasive and …See details»
Analytical Validation of NavDx, a cfDNA-Based Fragmentomic …
Abstract. The NavDx ® blood test analyzes tumor tissue modified viral (TTMV)-HPV DNA to provide a reliable means of detecting and monitoring HPV-driven cancers. The test has been …See details»
Surveillance - NavDx
A single positive NavDx TTMV-HPV DNA Score was the first indication of recurrence in 97% ... Geneva, Switzerland: World Health Organization, 2007. 8. Mijares K, Ferrandino R, Chai R, et al. Circulating Tumor HPV DNA in …See details»
NavDx® Test Resolves Indeterminate Cancer Findings - Naveris
Jun 27, 2024 NavDx testing showed a high accuracy rate of 98% in resolving these indeterminate clinical disease statuses and correctly predicting the presence or absence of …See details»
Naveris - Career Page
The company’s NavDx® blood test, which uses proprietary technology to detect tumor tissue modified viral (TTMV®)-HPV DNA, is in use at leading cancer treatment centers and academic …See details»
Blood Test to Check for HPV+ Throat Cancer | Fauquier ENT Blog
Jun 16, 2021 There is now a blood test called NavDx that is commercially available that can evaluate for the presence of throat cancer due to HPV. HPV throat cancer has become one of …See details»
Naveris Presents New Data on the NavDx® test for HPV
Sep 30, 2024 Naveris will be exhibiting at the conference at Booth #718, where attendees can learn more about NavDx and its impact on optimizing surveillance of oropharyngeal cancer …See details»
Naveris Expands Availability of Test in Anal Cancer MRD Surveillance
Jan 13, 2025 Naveris, a provider of precision oncology diagnostics for viral-induced cancers, announced the expanded commercial availability of the NavDx test for Molecular Residual …See details»
During Treatment - NavDx
Monitoring their TTMV-HPV DNA Score with NavDx during CRT may help guide personalized treatment decisions. ... Geneva, Switzerland: World Health Organization, 2007. 8. Mijares K, …See details»
NavDx® Advances Highlighted at 2024 ASTRO Annual Meeting
Sep 28, 2024 WALTHAM, Mass. – Naveris, Inc., the leader in precision oncology diagnostics for viral-induced cancers, today announced the presentation of new data at the 66th Annual …See details»
Patient FAQs - NavDx
NavDx is a test for tumors that are positive for human papillomavirus (HPV). Any patient previously diagnosed with HPV-positive head and neck cancer (cancer of the mouth and …See details»
Naveris, Mayo Clinic Begin Trial of Circulating Tumor DNA Test
Apr 12, 2023 NavDx was developed by researchers at the University of North Carolina. It uses digital PCR to detect tumor-modified HPV DNA. In a study involving 115 patients by the UNC …See details»
New NavDx® Data Shared at 2024 AAO-HNS Annual Meeting
Sep 27, 2024 WALTHAM, Mass. – Naveris, Inc., the leader in precision oncology diagnostics for viral-induced cancers, today announced the presentation of new data at the 2024 Annual …See details»